by Richard Daverman, PhD
November 28, 2012 -- Hutchison Chi-Med and Nestlé announced the formation of a major new JV based on Chi-Med’s expertise in traditional Chinese medicines. The JV, which will be called Nutrition Science Partners Limited, will focus on innovative gastrointestinal TCM-based medicines and nutritional products. Although the description sounds like an OTC venture, it also includes Chi-Med’s lead drug candidate, HMPL-004, a TCM-derived drug. HMPL-004 will soon begin Phase III trials as a treatment for ulcerative colitis and Crohn’s disease. More details....
Stock Symbol: (AIM: HCM)
